Radiopharmaceuticals for targeting the angiogenesis marker αvβ3

Quarterly Journal of Nuclear Medicine

Volumn 47, Issue 3, 2003, Pages 209-220

  McQuade, P ^a   Knights, L C ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neovascularization, pathologic; Radiopharmaceuticals; Vitronectin

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BITISTATIN CU 64; ARCITUMOMAB TC 99M; ARGINYLGLYCYLASPARTYLSERYLCYSTEINYLARGINYLGLYCYLASPARTYLSERYLTYROSINE; BARBOURIN; BITISTATIN; BITISTATIN I 125; CHELATING AGENT; DEPREOTIDE TC 99M; DISINTEGRIN; DISINTEGRIN I 123; ECHISTATIN; FIBRINOGEN I 125; HALYSIN; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; HISTIDYLLYSYLPROLYLGLUTAMINYLVALYLTHREONYLARGINYLGLYCYLASPARTYLVALYL PHENYLALANYLTHREONYLGLUTAMYLGLYCINE AMIDE; HISTIDYLLYSYLPROLYLGLUTAMINYLVALYLTHREONYLGLYCYLGLYCYLGLYCYLVALYL PHENYLALANYLTHREONYLGLUTAMYLGLYCINE AMIDE; INTEGRIN; KISTRIN; MAMBIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3 IN 111; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; RADIOACTIVE IODINE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITRONECTIN RECEPTOR;

ALPHA CHAIN; ANGIOGENESIS; BETA CHAIN; BLOOD VESSEL; DRUG EXCRETION; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; IMAGING SYSTEM; INJECTION; ISOTOPE LABELING; MACROMOLECULE; MOLECULAR BIOLOGY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; RADIOACTIVITY; RECEPTOR BINDING; REVIEW; SOLID TUMOR; TUMOR;

ANIMALS; HUMANS; INTEGRIN ALPHAVBETA3; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIOISOTOPES; RADIOPHARMACEUTICALS; TUMOR MARKERS, BIOLOGICAL;

EID: 0142074843     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. 123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J of Nucl Med 1993;20:716-31.
2. Society of Nuclear Medicine Categorical Seminar. Angiogenesis: Background and Introduction. Angiogenesis: Basic Principles and Potential Opportunities; 2001; Toronto, CA 2001.
3. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6.
4. Keshet E, Ben-Sasson SA. Anticancer drug targets: Approaching angiogenesis. J Clin Invest 1999;104:1497-501.
5. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
6. Ruoslahti E. Integrins. J Clin Invest 1991;87:1-5.
7. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of the integrins. Med Res Rev 1994;14:195-228.
8. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proceedings of the National Academy of Sciences of the United States of America 1987;84:6471-5.
9. Dejana E, Languino LR, Colella S, Corbascio GC, Plow E, Ginsberg M et al. The localization of a platelet GpIIb-IIIa-related protein in endothelial cell adhesion structures. Blood 1988;71:566-72.
10. Charo IF, Nannizzi I, Smith JW, Cheresh DA. The vitronectin receptor avb3 binds fibronectin and acts in concert with a5b1 in promoting cellular attachment and spreading of fibronectin. J Cell Biol 1990;111:2795-800.
11. Kramer RH, Cheng YF, Clyman R. Human microvascular endothelial cell use b1 and b3 integrin receptor complexes to attach laminin. J Cell Biol 1990;111:1233-43.
12. Lawler J, Weinstein R, Hynes RO. Cell attachment to thrombosponding: The role of arg-gly-asp, calcium and integrin receptors. J Cell Biol 1988;107:2351-61.
13. Denis C, Williams JA, Lu X, Meyer D, Baruch D. Solid-phase von Willebrand factor contains a conformationally active RGD motif that mediates endothelial cell adhesion through the avb3 receptor. Blood 1993;82:3622-30.
14. Sriramarao O, Mendler M, Bourdon MA. Endothelial cell attachment and spreading on human tenascin is mediated by a2b1 and avb3 integrins. J Cell Sci 1993;105:1001-12.
15. Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, Colucci S et al. Recognition of osteopontin and related peptides by an α v β 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 1991;266:20369-74.
16. Horton MA, Taylor ML, Arnett TR, Helfrich MH. Arg-gly-asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp Cell Res 1991;206:368-75.
17. Pfaff M, Aumailley M, Specks U, Knolle J, Zerwes HG, Timpl R. Integrin and arg-gly-asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. Exp Cell Res 1993;206:167-76.
18. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin in Cell Biol 1993;5:864-8.
19. Loftus JC, O'Toole TE, Plow EF, Glass A, Frelinger AL, Ginsberg MH. A b3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science 1990;249:915-8.
20. Smith JW, Cheresh DA. Labeling of integrin α V β3 with 58Co(III). J Biol Chem 1991;266:11429-32.
21. Tozer EC, Liddington RC, Sutcliffe MJ, Smeeton AH, Loftus JC. Ligand binding to integrin aIIbb3 is dependent on a MIDAS-like domain in the b3 subunit. J Biol Chem 1996;271:21978-84.
22. Suehiro K, Smith JW, Plow EF. The ligand recognition specificity of b3 integrins. J Biol Chem 1996; 271:10365-71.
23. Byzova TV, Rabbani R, D'Souza SE, Plow EF. Role of integrin α(v)-β3 in vascular biology. Thromb Haemost 1998;80:726-34.
24. D'Souza SE, Haas TA, Piotrowicz RS, Byres-Ward V, McGrath DE, Soule HR et al. Ligand and cation binding are dual functions of a discrete segment of the integrin beta-3 subunit: Cation displacement form this site is implicated in ligand binding. Cell 1994;79:659-67.
25. 3 integrins in hemostasis and vascular biology. Thromb Haemost 1995;74:149-55.
26. Brooks PC, Cheresh DA, Clark AF. Requirement of vascular integrin v v β 3 for angiogenesis. Science 1994;264:569-71.
27. Perlot RL, Jr., Shapiro IM, Mansfield K, Adams CS. Matrix regulation of skeletal cell apoptosis II: Role of Arg-Gly-Asp-containing peptides. J Bone Miner Res 2002;17:66-76.
28. Albelda SM, Mette SA, Elder DE, Stewart RM, Damjanovich L, Herlyn M et al. Integrin distribution in malignant melanoma: Association of the β (3) subunit with tumor progression. Cancer Res 1990;50:6757-64.
29. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the α (v) β (3) integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991;88:1924-32.
30. Sipkins D, Cheresh D, Kazemi M, Nevin L, Bednarski M, Li K. Detection of tumor angiogenesis in vivo by αVβ3-targeted magnetic resonance imaging. Nat Med 1998;4:623-626.
31. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 1998;25:1383-9.
32. Sutcliffe-Goulden Julie L, O'Doherty Michael J, Marsden Paul K, Hart Ian R, Marshall John F, Bansal Sukvinder S. Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging 2002;29:754-9.
33. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991;291:50-4.
34. Pfaff M, Tangemann K, Müller B, Gurrath M, Müller G, Kessler H et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by aIIbb3, avb3 and a5b1 integrins. J Biol Chem 1994;269:20233-8.
35. Koivunen E, Arap W, Rajotte D, Lahdenranta J, Pasqualini R. Identification of receptor ligands with phage display peptide libraries. J Nucl Med 1999;40:883-8.
36. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G et al. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
37. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct av integrins. Science 1995;270:1500-2.
38. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A et al. N-Methylated cyclic RGD peptides as highly active and selective α(V)β(3) integrin antagonists. J Med Chem 1999;42:3033-40.
39. Ogawa M, Hatano K, Oishi S, Kawasumi Y, Fujii N, Kawaguchi M et al. Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo α(V)β(3) integrin related tumor imaging(1). Nucl Med Biol 2003;30:1-9.
40. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001;48:151-7.
41. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles Floyd H, Stins M, Shimada H et al. α v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002;98:690-7.
42. 3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med 1999;40:1061-71.
43. Schraa Astrid J, Kok Robbert J, Berendsen Agnes D, Moorlag Henk E, Bos Erwin J, Meijer Dirk KF et al. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. J Contr Rel 2002;83:241-51.
44. Savill J, Dransfield I, Hogg N, Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990;343:170-3.
45. Pijuan-Thompson V, Gladson CL. Ligation of integrin α5β1 is required for internalization of vitronectin by integrin alphavbeta3. J Biol Chem 1997;272:2736-43.
46. Memmo LM, McKeown-Longo P. The αvβ5 integrin functions as an endocytic receptor for vitronectin. J Cell Sci 1998;111:425-33.
47. Van Hagen PM, Breeman WAP, Bernard HF, Schaar M, Krenning EP, De Jong M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000;8:186-98.
48. 90Y-labeled avb3 antagonists: Promising tracer for tumor induced angiogenesis. J Nucl Med 2000;41:41P.
49. Haubner R, Wester H-J, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL et al. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-36.
50. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
51. Janssen Marcel L, Oyen Wim J, Dijkgraaf I, Massuger Leon F, Frielink C, Edwards DS et al. Tumor targeting with radiolabeled α(v)β(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-51.
52. Janssen MLH, Oyen WJG, Edwards DS, Barnett JA, Rajopadhye M, Liu S. Tumor targeting with radiolabeled integrin avb3 binding RGD peptides in a nude mice model. J Nucl Med 2001;42:126P-7.
53. Kok RJ, Schraa AJ, Bos EJ, Moorlag HE, Asgeirsdottir SA, Everts M et al. Preparation and functional evaluation of RGD-modified proteins as α(v)β(3) integrin directed therapeutics. Biocon Chem 2002;13:128-35.
54. Saiki I, Murata J, Matsuno K, Ogawa R, Nishi N, Tokura S et al. Anti-metastatic and anti-invasive effects of polymeric Arg-Gly-Asp (RGD) peptide, poly(RGD), and its analogues. Jpn J Cancer Res 1990;81:660-7.
55. Saiki I, Murata J, Makabe T, Nishi N, Tokura S, Azuma I. Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly(RGD). Jpn J Cancer Res 1990;81:668-75.
56. Saiki I, Murata J, Iida J, Nishi N, Sugimura K, Azuma I. The inhibition of murine lung metastasis by synthetic polypeptides [-poly(arg-gly-asp) and poly(tyr-ile-gly-ser-arg)] with a core sequence of cell adhesion molecules. Br J Cancer 1989;59:194-7.
57. Saiki I, Iida J, Murata J, Ogawa R, Nishi N, Sugimura K et al. Inhibition of the metastasis of murine malignant melanoma by synthetic polymeric peptides containing core sequences of cell-adhesive molecules. Cancer Res 1989;49:3815-22.
58. Saiki I, Iida J, Azuma I, Nishi N, Matsuno K. Biological activities of synthetic polypeptides containing a repetitive core sequence (Arg-Gly-Asp) of cell adhesion molecules. Int J Biol Macromol 1989;11:23-5.
59. Murata J, Saiki I, Iida J, Azuma I, Kawahara H, Nishi N et al. Inhibition of tumour cell adhesion by anti-metastatic polypeptide containing a repetitive Arg-Gly-Asp sequence. Int J Biol Macromol 1989;11:226-32.
60. Murata J, Saiki I, Ogawa R, Nishi N, Tokura S, Azuma I. Molecular properties of poly(RGD) and its binding capacities to metastatic melanoma cells. Int J Peptide Protein Res 1991;38:212-7.
61. Saiki Y, Yoneda J, Igarashi Y, Aoki M, Kusunose N, Ono K et al. Antimetastatic activity of polymeric RGDT peptides conjugated with poly(ethylene glycol). Jpn J Cancer Res 1993;84:558-65.
62. Kawasaki K, Namikawa M, Yamashiro Y, Hama T, Mayumi T. Preparation of [Arg-Gly-Asp]-[amino-poly(ethylene glycol)] hybrids and their inhibitory effect on experimental metastasis. Chem Pharm Bull 1991;39:3373-5.
63. Pfaff M, McLane MA, Beviglia L, Niewiarowski S, Timpl R. Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins αIIb β3, αV β3 and α5 β1 and in cell adhesion inhibition. Cell Adhes Commun 1994;2:491-501.
64. Scarborough RM, Rose JW, McNaughton MA, Phillips DR, Nannizzi L, Arfsten A et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 1993;268:1058-65.
65. McLane MA, Vijay-Kumar S, Marcinkiewicz C, Calvete JJ, Niewiarowski S. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of α IIb β 3 and α v β 3 integrins. FEBS Lett 1996;391:139-43.
66. Marcinkiewicz C, Vijay-Kumar S, McLane MA, Niewiarowski S. Significance of RGD loop and C-terminal domain of echistatin for recognition of aIIbb3 and avb3 integrins and expression of ligand-induced binding site. Blood 1997;90:1565-75.
67. Wierzbicka-Patynowski I, Niewiarowski S, Marcinkiewicz C, Calvete JJ, Marcinkiewicz MM, McLane MA. Structural requirements of echistatin for the recognition of avb3 and a5b1 integrins. J Biol Chem 1999;274:37809-14.
68. Juliano D, Wang Y, Marcinkiewicz C, Rosenthal LA, Stewart GJ, Niewiarowski S. Disintegrin interaction with α V β 3 integrin on human umbilical vein endothelial cells: Expression of ligand-induced binding site on β 3 subunit. Exp Cell Res 1996;225:132-42.
69. Sheu J-R, Yen M-H, Kan Y-C, Hung W-C, Chang P-T, Luk H-N. Inhibition of angiogenesis in vitro and in vivo: Comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-avb3 integrin monoclonal antibody. Biochim et Biophys Acta 1997;1336:445-54.
70. Tselepis VH, Green LJ, Humphries MJ. An RGD to LDV motif conversion within the disintegrins kistrin generates an integrin antagonist that retains potency but exhibits altered receptor specificity. Evidence for a functional equivalence of acidic integrin-binding motifs. J Biol Chem 1997;272:21341-8.
71. Zalutsky MR, Noska MA, Colapinto EV, Garg PK, Bigner DD. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. Cancer Res 1989;49:5543-9.
72. Knight LC, Maurer AH, Romano JE. Comparison of Iodine-123-disintegrins for imaging thrombi and emboli in a canine model. J Nucl Med 1996;37:476-82.
73. Knight LC, Romano JE, Maurer AH. In vitro platelet binding compared with in vivo thrombus imaging using aIIbb3-targeted radioligands. Thromb Haemost 1998;80:845-51.
74. 99mTc-labeled bitistatin, a platelet-binding polypeptide from viper venom. J Nucl Med 2000;41:1056-64.
75. Knight LC, Baidoo KE, Marmion ME, Romano JE. Tc-99m tricarbonyl labeling of DTPA-bitistatin for imaging thrombi and emboli. Nucl Med Commun 2000;21:589.
76. Baidoo KE, Knight L, Romano JE, Gabriel JL, Maurer AH. Synthesis and evaluation of a new bifunctional chelator designed for labeling biomolecules by the technetium-tricarbonyl technology. J Labelled Comp Radiopharm 2001;44:S66-8.
77. Knight LC, McCarthy D, Romano JE, Welch MJ. Preliminary evaluation of radiolabeled bitistatin as a potential agent for targeting integrins in tumor angiogenesis with PET. J Labelled Cpd Radiopharm 2001;44:S84-6.
78. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M et al. Integrin distribution in malignant melanoma: Association of the β 3 subunit with tumor progression. Cancer Res 1990;50:6757-64.
79. Scheibler L, Mierke DF, Bitan G, Rosenblatt M, Chorev M. Identification of a contact domain between echistatin and the integrin α(v)β(3) by photoaffinity cross-linking. Biochemistry 2001;40:15117-26.
80. Knight LC, Romano JE, Maurer AH. In vitro platelet binding compared with in vivo thrombus imaging using α(IIb)β3-targeted radioligands. Thromb Haemost 1998;80:845-51.
81. Lewis MR, Kao JY, Anderson AL, Shively JE, Raubitschek A. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Biocon Chem 2001;12:320-4.